Multispecific Antibody Development Clinical Trials Sales Market Size Insight
June 30, 2023 07:28 ET | KuicK Research
Delhi, June 30, 2023 (GLOBE NEWSWIRE) -- The development of multispecific antibodies, which have the potential to change the way cancer is treated, has been positively influenced by the commercial...
Global Tetraspecific Antibody Market Opportunity Clinical Development Report
March 22, 2023 08:17 ET | KuicK Research
Delhi, March 22, 2023 (GLOBE NEWSWIRE) -- Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 Report Highlights: Global Tetraspecific...
Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences
March 29, 2022 10:56 ET | Cytovia Therapeutics
AVENTURA, Fla. and NATICK, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
October 12, 2021 12:24 ET | Cytovia Therapeutics
AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...
Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline
September 13, 2021 10:08 ET | Cytovia Therapeutics
Cytovia eligible for up to $400 million in licensing milestones for Greater China rightsCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma AVENTURA,...
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020
September 29, 2020 16:00 ET | Cytovia Therapeutics
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in...
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic
August 12, 2020 09:04 ET | Cytovia Therapeutics
NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager...
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
June 03, 2020 13:25 ET | Cytovia Therapeutics
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...
Hebrew University to Collaborate with Cytovia Therapeutics
March 18, 2020 09:00 ET | Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...
Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy
January 06, 2020 08:00 ET | Cytovia Therapeutics
SAN FRANCISCO and NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, a biopharmaceutical company, and the University of California, San Francisco (UCSF) announced today that they have...